Delanterone

Delanterone
Clinical data
Other names	GBR-21162; 1α-Methylandrosta-4,16-dien-3-one
Identifiers
	IUPAC name (1S,8S,9S,10R,13R,14S)-1,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one;
CAS Number	63014-96-0;
PubChem CID	205969;
ChemSpider	178468;
UNII	AM2KZ47R0J;
ChEMBL	ChEMBL2104221;
CompTox Dashboard (EPA)	DTXSID401024291 ;
Chemical and physical data
Formula	C20H28O
Molar mass	284.443 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CC(=O)C=C2C1(C3CCC4(C=CCC4C3CC2)C)C;
	InChI InChI=1S/C20H28O/c1-13-11-15(21)12-14-6-7-16-17-5-4-9-19(17,2)10-8-18(16)20(13,14)3/h4,9,12-13,16-18H,5-8,10-11H2,1-3H3/t13-,16-,17-,18-,19-,20-/m0/s1; Key:GDONNNQFENTLQC-VWTPSIDOSA-N;

Delanterone (INNTooltip International Nonproprietary Name) (developmental code name GBR-21162), also known as 1α-methylandrosta-4,16-dien-3-one, is a steroidal antiandrogen described as an anti-acne agent which was never marketed.^[1]^[2]^[3] The compound showed poor efficacy as an antiandrogen in vivo in animals, suggestive of low activity or a short terminal half-life, and likely in relation to this was not further developed.^[3] It was described and characterized in the literature in 1977.^[1]^[3]